Treatment of Helicobacter Pylori Infection

Therapy of Digestive Disorders

Volumn , Issue , 2006, Pages 277-290

  Peura, David A ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882545748     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-0317-5.50024-8     Document Type: Chapter

References (116)

1. Marshall B, Warren J Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984, 1(8390):1311-1315.
2. Suerbaum S, Michetti P Helicobacter pylori infection. N Engl J Med 2002, 347:1175-1186.
3. Rowland M, Kumar D, Daly L, et al. Low rates of Helicobacter pylori reinfection in children. Gastroenterology 1999, 117:336-341.
4. Neale KR, Logan RP The epidemiology and transmission of Helicobacter pylori infection in children. Aliment Pharmacol Ther 1995, 9(Suppl 2):77-84.
5. Frenck RW, Clemens J Helicobacter in the developing world. Microbes Infect 2003, 5:705-713.
6. Parsonnet J The incidence of Helicobacter pylori infection. Aliment Pharmacol Ther 1995, 9(Suppl 2):45-51.
7. Kivi M, Tindberg Y, Sorberg M, et al. Concordance of Helicobacter pylori strains within families. J Clin Microbiol 2003, 41:5604-5608.
8. Megraud F Transmission of Helicobacter pylori: faecal-oral versus oral-oral route. Aliment Pharmacol Ther 1995, 9(Suppl 2):85-91.
9. Rothenbacher D, Brenner H Burden of Helicobacter pylori and H. pylori-related diseases in developed countries: recent developments and future implications. Microbes Infect 2003, 5:693-703.
10. Everhart JE, Kruszon-Moran D, Perez-Perez GI, et al. Seroprevalence and ethnic differences in Helicobacter pylori infection among adults in the United States. J Infect Dis 2000, 181:1359-1363.
11. Blaser MJ Role of vacA and the cagA locus of Helicobacter pylori in human disease. Aliment Pharmacol Ther 1996, 10(Suppl 1):73-77.
12. Weel JF, Van Der Hulst RW, Gerrits Y, et al. The interrelationship between cytotoxin-associated gene A, vacuolating cytotoxin, and Helicobacter pylori-related diseases. J Infect Dis 1996, 173:1171-1175.
13. Huang JQ, Zheng GF, Sumanac K, et al. Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology 2003, 125:1636-1644.
14. El-Omar EM The importance of interleukin 1beta in Helicobacter pylori associated disease. Gut 2001, 48:743-747.
15. El-Omar EM, Carrington M, Chow WH, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000, 404:398-402.
16. Laine L, Schoenfeld P, Fennerty MB Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials. Ann Intern Med 2001, 134:361-369.
17. Moayyedi P, Soo S, Deeks J, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2000, CD002096.
18. Vakil NB Review article: gastro-oesophageal reflux disease and Helicobacter pylori infection. Aliment Pharmacol Ther 2002, 16(Suppl1):47-51.
19. Leontiadis GI, Sharma VK, Howden CW Non-gastrointestinal tract associations of Helicobacter pylori infection. Arch Intern Med 1999, 159:925-940.
20. Ciociola AA, Mcsorley DJ, Turner K, et al. Helicobacter pylori infection rates in duodenal ulcer patients in the United States may be lower than previously estimated. Am J Gastroenterol 1999, 94:1834-1840.
21. Laine L, Hopkins RJ, Girardi LS Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overstated? A meta-analysis of rigorously designed trials. Am J Gastroenterol 1998, 93:1409-1415.
22. Huang JQ, Sridhar S, Hunt RH Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002, 359:14-22.
23. Chan F, To K, Wu J, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 2002, 359:9-13.
24. Chan F, Chung S, Suen B, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001, 344:967-973.
25. Goldstein J, Correa P, Zhao W, et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol 2001, 96:1019-1027.
26. Infection with Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum 1994, 61:177-240. [No authors listed].
27. Fischbach W, Goebeler-Kolve ME, Dragosics B, et al. Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series. Gut 2004, 53:34-37.
28. Laine L, Dhir V Helicobacter pylori eradication does not worsen quality of life related to reflux symptoms: a prospective trial. Aliment Pharmacol Ther 2002, 16:1143-1148.
29. Rautelin H, Lehours P, Megraud F Diagnosis of Helicobacter pylori infection. Helicobacter 2003, 8:13-20.
30. Chiba N, Veldhuyzen van Zanten SJ *C-Urea breath tests are the noninvasive method of choice for Helicobacter pylori detection. Can J Gastroenterol 1999, 13:681-683.
31. Peura DA, Pambianco DJ, Dye KR, et al. Microdose *C-urea breath test offers diagnosis of Helicobacter pylori in 10 minutes. Am J Gastroenterol 1996, 91:233-238.
32. Vaira D, Malfertheiner P, Megraud F, et al. Diagnosis of Helicobacter pylori infection by HpSA test. European Helicobacter pylori HpSA Study Group. Lancet 1999, 354:1732.
33. Vaira D, Vakil N, Menegatti M, et al. The stool antigen test for detection of Helicobacter pylori after eradication therapy. Ann Intern Med 2002, 136:280-287.
34. Laine L, Estrada R, Trujillo M, et al. Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori. Ann Intern Med 1998, 129:547-550.
35. Manes G, Balzano A, Iaquinto G, et al. Accuracy of the stool antigen test in the diagnosis of Helicobacter pylori infection before treatment and in patients on omeprazole therapy. Aliment Pharmacol Ther 2001, 15:73-79.
36. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002, 16:167-180.
37. Howden CW, Hunt RH Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998, 93:2330-2338.
38. Lam SK, Talley NJ Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998, 13:1-12.
39. Fischbach LA, Goodman KJ, Feldman M, et al. Sources of variation of Helicobacter pylori treatment success in adults worldwide: a meta-analysis. Int J Epidemiol 2002, 31:128-139.
40. Lambert JR Pharmacology of bismuth-containing compounds. Rev Infect Dis 1991, 13(Suppl 8):S691-S695.
41. Lambert JR, Midolo P The actions of bismuth in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1997, 11(Suppl1):27-33.
42. Tillman LA, Dixon JS, Wood JR Review article: safety of bismuth in the treatment of gastrointestinal diseases. Aliment Pharmacol Ther 1996, 10(4):459-467.
43. Van der Wouden EJ, Thijs JC, Kusters JG, et al. Mechanism and clinical significance of metronidazole resistance in Helicobacter pylori. Scand J Gastroenterol Suppl 2001, 36:10-14.
44. Lambert JR Pharmacology of the gastric mucosa: a rational approach to Helicobacter polytherapy. Gastroenterology 1996, 111:521-523.
45. Graham DY, Opekun AR, Klein PD Clarithromycin for the eradication of Helicobacter pylori. J Clin Gastroenterol 1993, 16:292-294.
46. Malanoski GJ, Eliopoulos GM, Ferraro MJ, et al. Effect of pH variation on the susceptibility of Helicobacter pylori to three macrolide antimicrobial agents and temafloxacin. Eur J Clin Microbiol Infect Dis 1993, 12:131-133.
47. Gustavson LE, Kaiser JF, Edmonds AL, et al. Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. Antimicrob Agents Chemother 1995, 39:2078-2083.
48. Megraud F, Trimoulet P, Lamouliatte H, et al. Bactericidal effect of amoxicillin on Helicobacter pylori in an in vitro model using epithelial cells. Antimicrob Agents Chemother 1991, 35:869-872.
49. Berry V, Woodnutt G Bactericidal and morphological effects of amoxicillin on Helicobacter pylori. Antimicrob Agents Chemother 1995, 39:1859-1861.
50. McNulty CA, Dent JC Susceptibility of clinical isolates of Campylobacter pylori to twenty-one antimicrobial agents. Eur J Clin Microbiol Infect Dis 1988, 7:566-569.
51. Belli WA Partial characterization and effect of omeprazole on ATPase activity in Helicobacter pylori by using permeabilized cells. Antimicrob Agents Chemother 1995, 39:1717-1720.
52. Nagata K, Iwahi T, Shimoyama T, et al. Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori: unique action selective for H. pylori cells. Antimicrob Agents Chemother 1993, 37:769-774.
53. Marshall BJ, Goodwin CS, Warren JR, et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988, 2:1437-1442.
54. Weil J, Bell G, Powell K, et al. Helicobacter pylori infection treated with a tripotassium dicitrato bismuthate and metronidazole combination. Aliment Pharmacol Ther 1990, 4:651-657.
55. Drumm B, Sherman P, Chiasson D, et al. Treatment of Campylobacter pylori-associated antral gastritis in children with bismuth subsalicylate and ampicillin. J Pediatr 1988, 113:908-912.
56. Graham DY, Klein PD, Evans DG, et al. Simple noninvasive method to test efficacy of drugs in the eradication of Helicobacter pylori infection: the example of combined bismuth subsalicylate and nitrofurantoin. Am J Gastroenterol 1991, 86:1158-1162.
57. Pommerien W, Idstrom JP, Wrangstadh M, et al. Pharmacokinetic and pharmacodynamic interactions between omeprazole and amoxycillin in Helicobacter pylori-positive healthy subjects. Aliment Pharmacol Therapeut 1996, 10:295-301.
58. Bayerdorffer E, Miehlke S, Mannes G, et al. Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. Gastroenterology 1995, 108:1412-1417.
59. Labenz J, Gyenes E, Ruhl G, et al. Amoxicillin plus omeprazole versus triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease: a prospective, randomized, and controlled study. Gut 1993, 34:1167-1170.
60. Al-Assi MT, Cole RA, Karttunen TJ, et al. Treatment of Helicobacter pylori infection with omeprazole-amoxicillin combination therapy versus ranitidine/sodium bicarbonate-amoxicillin. Am J Gastroenterol 1995, 90:1411-1414.
61. Laine L, Stein C, Neil G Limited efficacy of omeprazole-based dual and triple therapy for Helicobacter pylori: a randomized trial employing 'optimal' dosing. Am J Gastroenterol 1995, 90:1407-14010.
62. Harford W, Lanza F, Arora A, et al. Double-blind, multicenter evaluation of lansoprazole and amoxicillin dual therapy for the cure of Helicobacter pylori infection. Helicobacter 1996, 1:243-250.
63. Labenz J, Leverkus F, Borsch G Omeprazole plus amoxicillin for cure of Helicobacter pylori infection. Factors influencing the treatment success. Scand J Gastroenterol 1994, 29:1070-1075.
64. Tanigawara Y, Aoyama N, Kita T, et al. CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. Clin Pharmacol Ther 1999, 66:528-534.
65. Logan RP, Gummett PA, Schaufelberger HD, et al. Eradication of Helicobacter pylori with clarithromycin and omeprazole. Gut 1994, 35:323-326.
66. Laine L, Fennerty M, Osato M, et al. Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. Am J Gastroenterol 2000, 95:3393-3398.
67. Peterson WL, Ciociola AA, Sykes DL, et al. Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H. pylori and reducing ulcer recurrence. RBC H. pylori Study Group. Aliment Pharmacol Ther 1996, 10:251-261.
68. Laheij RJ, Rossum LG, Jansen JB, et al. Evaluation of treatment regimens to cure Helicobacter pylori infection-a meta-analysis. Aliment Pharmacol Ther 1999, 13:857-864.
69. Graham DY, Lew GM, Evans DG, et al. Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing. A randomized controlled trial. Ann Intern Med 1991, 115:266-269.
70. De Boer W, Driessen W, Jansz A, et al. Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection. Lancet 1995, 345:817-820.
71. Hosking SW, Ling TK, Chung SC, et al. Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: randomised controlled trial. Lancet 1994, 343:508-510.
72. Houben MH, Van De Beek D, Hensen EF, et al. A systematic review of Helicobacter pylori eradication therapy-the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther 1999, 13:1047-1055.
73. Borody TJ, George LL, Brandl S, et al. Helicobacter pylori eradication with doxycycline-metronidazole-bismuth subcitrate triple therapy. Scand J Gastroenterol 1992, 27:281-284.
74. Al-Assi MT, Ramirez FC, Lew GM, et al. Clarithromycin, tetracycline, and bismuth: a new non-metronidazole therapy for Helicobacter pylori infection. Am J Gastroenterol 1994, 89:1203-1205.
75. Segura AM, Gutierrez O, Otero W, et al. Furazolidone, amoxycillin, bismuth triple therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 1997, 11:529-532.
76. Laine L, Estrada R, Trujillo M, et al. Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori. Am J Gastroenterol 1997, 92:2213-2215.
77. Savarino V, Mansi C, Mele MR, et al. A new 1-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus two antibiotics. Aliment Pharmacol Ther 1997, 11:699-703.
78. Wyeth JW, Pounder RE, Duggan AE, et al. The safety and efficacy of ranitidine bismuth citrate in combination with antibiotics for the eradication of Helicobacter pylori. Aliment Pharmacol Ther 1996, 10:623-630.
79. Gisbert JP, Gonzalez L, Calvet X, et al. Helicobacter pylori eradication: proton pump inhibitor vs ranitidine bismuth citrate plus two antibiotics for 1 week-a meta-analysis of efficacy. Aliment Pharmacol Ther 2000, 14:1141-1150.
80. Lind T, Megraud F, Unge P, et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 1999, 116:248-253.
81. Yousfi MM, El-Zimaity HM, Al-Assi MT, et al. Metronidazole, omeprazole and clarithromycin: an effective combination therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 1995, 9:209-212.
82. Dohil R, Israel Dm, Hassall E Effective 2-wk therapy for Helicobacter pylori disease in children. Am J Gastroenterol 1997, 92:244-247.
83. Harris AW, Pryce DI, Gabe SM, et al. Lansoprazole, clarithromycin and metronidazole for seven days in Helicobacter pylori infection. Aliment Pharmacol Ther 1996, 10:1005-1008.
84. Laine L, Suchower L, Frantz J, et al. Twice-daily, 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: results of three multicenter, double-blind, United States trials. Am J Gastroenterol 1998, 93:2106-2112.
85. Fennerty MB, Kovacs TO, Krause R, et al. A comparison of 10 and 14 days of lansoprazole triple therapy for eradication of Helicobacter pylori. Arch Intern Med 1998, 158:1651-1656.
86. Catalano F, Branciforte G, Catanzaro R, et al. Comparative treatment of Helicobacter pylori-positive duodenal ulcer using pantoprazole at low and high doses versus omeprazole in triple therapy. Helicobacter 1999, 4:178-184.
87. Miwa H, Ohkura R, Murai T, et al. Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole. Aliment Pharmacol Ther 1999, 13:741-746.
88. Adamek RJ, Suerbaum S, Pfaffenbach B, et al. Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin-influence on treatment outcome. Am J Gastroenterol 1998, 93:386-389.
89. Treiber G, Wittig J, Ammon S, et al. Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study). Arch Intern Med 2002, 162:153-160.
90. Lara LF, Cisneros G, Gurney M, et al. One-day quadruple therapy compared with 7-day triple therapy for Helicobacter pylori infection. Arch Intern Med 2003, 163:2079-2084.
91. Kimura K, Ido K, Saifuku K, et al. A 1-h topical therapy for the treatment of Helicobacter pylori infection. Am J Gastroenterol 1995, 90:60-63.
92. Kihira K, Satoh K, Saifuku K, et al. Endoscopic topical therapy for the treatment of Helicobacter pylori infection. J Gastroenterol 1996, 31(Suppl9):66-68.
93. Dore MP, Leandro G, Realdi G, et al. Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. Dig Dis Sci 2000, 45:68-76.
94. Meyer JM, Silliman NP, Wang W, et al. Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999. Ann Intern Med 2002, 136:13-24.
95. Osato MS, Reddy R, Reddy SG, et al. Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch Intern Med 2001, 161:1217-1220.
96. Duck W Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis 2004, 10:1088-1094.
97. Oleastro M, Menard A, Santos A, et al. Real-time PCR assay for rapid and accurate detection of point mutations conferring resistance to clarithromycin in Helicobacter pylori. J Clin Microbiol 2003, 41:397-402.
98. Abu-Mahfouz MZ, Prasad VM, Santogade P, et al. Helicobacter pylori recurrence after successful eradication: 5-year follow-up in the United States. Am J Gastroenterol 1997, 92:2025-2028.
99. Xia HX, Talley NJ, Keane CT, et al. Recurrence of Helicobacter pylori infection after successful eradication: nature and possible causes. Dig Dis Sci 1997, 42:1821-1834.
100. Kearney DJ Retreatment of Helicobacter pylori infection after initial treatment failure. Am J Gastroenterol 2001, 96:1335-1339.
101. Hojo M, Miwa H, Nagahara A, et al. Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection. Scand J Gastroenterol 2001, 36:690-700.
102. Fakheri H, Malekzadeh R, Merat S, et al. Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate. Aliment Pharmacol Ther 2001, 15:411-416.
103. Zullo A, Hassan C, De Francesco V, et al. A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication. Dig Liver Dis 2003, 35:232-236.
104. Perri F, Festa V, Clemente R, et al. Randomized study of two 'rescue' therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am J Gastroenterol 2001, 96:58-62.
105. Chen M, Lee A, Hazell S, et al. Immunisation against gastric infection with Helicobacter species: first step in the prophylaxis of gastric cancer?. Zentralbl Bakteriol 1993, 280:155-165.
106. Marchetti M, Arico B, Burroni D, et al. Development of a mouse model of Helicobacter pylori infection that mimics human disease. Science 1995, 267:1655-1658.
107. Ikewaki J, Nishizono A, Goto T, et al. Therapeutic oral vaccination induces mucosal immune response sufficient to eliminate long-term Helicobacter pylori infection. Microbiol Immunol 2000, 44:29-39.
108. Ghiara P, Rossi M, Marchetti M, et al. Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection. Infect Immun 1997, 65:4996-5002.
109. Michetti P, Kreiss C, Kotloff KL, et al. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology 1999, 116:804-812.
110. Kotloff KL, Sztein MB, Wasserman SS, et al. Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect Immun 2001, 69:3581-3590.
111. Chalker AF, Minehart HW, Hughes NJ, et al. Systematic identification of selective essential genes in Helicobacter pylori by genome prioritization and allelic replacement mutagenesis. J. Bacteriol 2001, 183:1259-1268.
112. Malfertheiner P, Megraud F, O'Morain C, et al. Current European concepts in the management of Helicobacter pylori infection-the Maastricht Consensus Report. The European Helicobacter Pylori Study Group (EHPSG). Eur J Gastroenterol Hepatol 1997, 9:1-2.
113. Chey WD, Fendrick AM Noninvasive Helicobacter pylori testing for the 'test-and-treat' strategy: a decision analysis to assess the effect of past infection on test choice. Arch Intern Med 2001, 161:2129-2132.
114. Fendrick AM, Chey WD, Margaret N, et al. Symptom status and the desire for Helicobacter pylori confirmatory testing after eradication therapy in patients with peptic ulcer disease. Am J Med 1999, 107:133-136.
115. Parsonnet J, Harris RA, Hack HM, et al. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. Lancet 1996, 348:150-154.
116. Ladabaum U, Chey WD, Scheiman JM, et al. Reappraisal of non-invasive management strategies for uninvestigated dyspepsia: a cost-minimization analysis. Aliment Pharmacol Ther 2002, 16:1491-1501.